Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: A method for determining the health status of an elderly individual by testing the sample extracted from the individual for the presence of biomarkers, the bio markers being autoantibodies to antigens comprising MAPK13, CD96, FKBP3, PPM1A, PHLDA1, GLRX3, FEN1 and AURKA, wherein the antigens may further comprise one or more of UBE2I, AAK1, YARS, ASPSCR1, CASP10, FHOD2, TCL1A and MAP4, wherein PHLDA1 and CD96 correspond to healthy, AURKA, FEN1, CASP10 and AAK1 correspond to intermediate health, and UBE2I, YARS, ASPSCR1, FHOD2, TCL1A, MAP4, MAPK13, FKBP3, PPM1A and GLRX3 correspond to unhealthy.

Abstract: The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: The disclosure provides compounds of Formula I, deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

Abstract: The disclosure provides at least one compound, reiterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), reiterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

Abstract: A structure is provided that reduces the stress generated in a semiconductor device package during cooling subsequent to solder reflow operations for coupling semiconductor devices to a printed circuit board (PCB). Stress reduction is provided by coupling solder lands to metal-layer structures using traces on the PCB that are oriented approximately perpendicular to lines from an expansion neutral point associated with the package. In many cases, especially where the distribution of solder lands of the semiconductor device package are uniform, the expansion neutral point is in the center of the semiconductor device package. PCB traces having such an orientation experience reduced stress due to thermal-induced expansion and contraction as compared to traces having an orientation along a line to the expansion neutral point.

Abstract: The disclosure provides at least one entity chosen from compounds of Formula (I) pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

Abstract: A structure is provided that reduces the stress generated in a semiconductor device package during cooling subsequent to solder reflow operations for coupling semiconductor devices to a printed circuit board (PCB). Stress reduction is provided by coupling solder lands to metal-layer structures using traces on the PCB that are oriented approximately perpendicular to lines from an expansion neutral point associated with the package. In many cases, especially where the distribution of solder lands of the semiconductor device package are uniform, the expansion neutral point is in the center of the semiconductor device package. PCB traces having such an orientation experience reduced stress due to thermal-induced expansion and contraction as compared to traces having an orientation along a line to the expansion neutral point.

Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomeulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: A method of taking a plurality of measurements of the magnetic field using the plurality of sensors; includes assessing the inductive magnetic excitation; and determining the likely distribution of magnetic sources on the surface of the hull by resolving a system of equations derived from modeling the physical phenomena at play, on the basis of the plurality of measurements taken and the assessed inductive magnetic excitation. The model describes the induced magnetic sources as a distribution of dipolar sources and the remanent magnetic sources as a distribution of monopolar sources. A device (6) for determining the magnetization of the hull of a ship for implementing the method is also described.

Abstract: The invention provides polypeptides comprising an amino acid sequence comprising at least one variation from wild-type HCV NS5B polymerase, the at least one variation selected from the group consisting of cysteine, isoleucine, valine, or proline at amino acid position 419; alanine, valine, or asparagine at amino acid position 482; valine, isoleucine, threonine, or serine at amino acid position 486; and isoleucine at amino acid position 494, as the amino acid positions are defined in SEQ ID NO: 1, and having Hepatitis C Virus (HCV) NS5B polymerase activity. Polynucleotides encoding the polypeptide, antibodies, host cells, compositions, and methods for detecting an HCV NS5B polymerase having resistance to a polymerase inhibitor also are provided.

Abstract: A method of improving the pharmacokinetics of VX-222 in a patient infected with HCV comprises co-administering VX-222 and VX-950 to the patient. A method of treating a patient infected with HCV comprises administering VX-222 and VX-950 to the patient, wherein VX-222 is in an amount of about 20 mg to about 400 mg, and wherein VX-950 is in an amount of about 100 mg to about 1,500 mg. A method of treating a patient infected with HCV comprises administering a therapeutically effective amount of VX-222, wherein VX-222 is administered at an amount of about 20 mg to about 2,000 mg once a day.

Abstract: A method of taking a plurality of measurements of the magnetic field using the plurality of sensors; includes assessing the inductive magnetic excitation; and determining the likely distribution of magnetic sources on the surface of the hull by resolving a system of equations derived from modeling the physical phenomena at play, on the basis of the plurality of measurements taken and the assessed inductive magnetic excitation. The model describes the induced magnetic sources as a distribution of dipolar sources and the remanent magnetic sources as a distribution of monopolar sources. A device (6) for determining the magnetization of the hull of a ship for implementing the method is also described.

Abstract: This glass-metal penetration is made from glass, a metal pin and a body. The glass is of the TA23 type and the pin is made using solid platinum/iridium (90/10).

Abstract: This glass-metal penetration is made from glass, a metal pin and a body. The glass is of the TA23 type and the pin is made using solid platinum/iridium (90/10).

Abstract: A multichannel optical amplifier having an adjustable gain set point is controlled to permit substantially constant gain tilt control during a gain set-point change so that the channel powers are maintained during system modification. To this end the amplifier comprises an erbium doped fibre (EDF) loop and associated pump amplifier for amplifying an optical signal comprising channels of different wavelengths, a variable optical attenuator (VOA) for controlling the gain of the amplifier by applying a loss profile that varies with wavelength so that the different channels are amplified in accordance with a required gain tilt, preferably a zero gain tilt, and a PI controller for applying a gain tilt adaptation profile to compensate for an inherent gain tilt to produce the required gain tilt.

Abstract: A DNA sequence isolated form a Nicotiana species (e.g., Nicotiana benthamiana) has SEQ ID NO: 1. The DNA sequence encodes a polypeptide having enzymatic activity for producing squalene. The polypeptide is referred to as squalene synthetase.

Abstract: The link includes two rigid inside tubes 4 and 5 for connection firstly to a vehicle chassis and secondly to the engine of the vehicle, a rigid hollow outer strength member 7 of composite material, said strength member 7 thus possessing two opposite walls 7a and 7b extending lengthwise, and two low-stiffness inside resilient pads 8 and 9 connecting respective ones of said inside tubes 4 and 5 to said opposite walls 7a and 7b of the outer strength member. The fibers of the composite material of the outer strength member 7 are crossed, and at least a fraction of them extend at an angle of more than .+-.30.degree. relative to the axis of the link. The link is applicable to any vehicle.